reported that a small molecule inhibitor of CREB (cAMP Response-Element Binding Protein), XX-650-23, interaction mostly affects apoptotic, cell-cycle, and survival pathways, which may represent a novel approach for AML therapy (19). This evidence concerns the gene CREB1 and acute myeloid leukemia.